Publications

Select Publications

Cisplatin-induced hearing loss in the treatment of cancer: 

Drögemöller BI, Wright GEB, Lo C, Le T, Brooks B, Bhavsar AP, Rassekh SR, Ross CJD, Carleton BC. Pharmacogenomics of Cisplatin-Induced Ototoxicity: Successes, Shortcomings and Future Avenues of Research. Clin Pharm Ther. 2019 Aug;106(2):350-359 PMID: 31012503

Clemens E, Meijer AJM, Broer L, Langer T, van der Kooi ALF, Uitterlinden AG, Kuehni C, Luisagarre M, Tomas K, Kruseova J, Winther JF, Kremer LCM, van Dulmen-den Broeder E, Tissing WJE, Grabow D, Binder H, Kaatsch P, Zehnhoff AM, Carleton B, Zolk O, van den Heuvel-Eibrink MM. Genetic Determinants of Ototoxicity during and after Childhood Cancer Treatment: Protocol for the PanCareLIFE study. JMIR Res Protoc. 2019 Mar 19;8(3):e11868. PMID: 30888333

Clemens E, Brooks B, de Vries ACH, van Grotel M, van den Heuvel-Eibrink M, Carleton B. A Comparison of the Muenster, SIOP Boston, Brock, Chang and CTCAE v4.03 Ototoxicity Grading Scales Applied to 3,799 Audiograms of Childhood Cancer Patients Treated with Platinum-Based Chemotherapy. PLOS ONE. 2019 Feb 14;14(2):e0210646. PMID: 30763334 

Drögemöller B, Brooks B, Monzon JG, Wright GEB, Liu G, Renouf DJ, Kollmannsberger C, Bedard P, Hayden MR, Gelmon K, Carleton B, Ross CJD. Further investigation of the role of ACYP2 and WFS1 pharmacogenomic variants in the development of cisplatin-induced ototoxicity in testicular cancer patients. Clin Cancer Res. 2018 Apr 15;24(8):1866-1871. PMID: 29358504 

Drögemöller BI, Monzon JG, Bhavsar AP, Borrie AE, Brooks B, Wright GEB, Liu G, Renouf DJ, Kollmannsberger CK, Bedard PL, Aminkeng F, Amstutz U, Hildebrand CA, Gunaretnam EP, Critchley C, Chen Z, Brunham LR, Hayden MR, Ross CJD, Gelmon KA, Carleton BC. Association between SLC16A5 genetic variation and cisplatin-induced ototoxic effects in adult patients with testicular cancer. JAMA Oncol. 2017 Nov 1;3(11):1558-1562. PMID: 28448657 

Bhavsar AP, Gunaretnam EP, Li Y, Hasbullah JS, Carleton BC, Ross CJ. Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines. PLoS One. 2017 Apr 13;12(4):e0175711. PMID: 28406961 

Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC and the CPNDS clinical recommendations group.  Clinical Practice Recommendations for the Management and Prevention of Cisplatin-induced Hearing Loss using Pharmacogenomics Markers. Ther Drug Monit. 2016 Aug;38(4):423-31. PMID: 26960170

Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dube MP, Hayden MR. Genetic markers of cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2014 Sep;96(3):296-8. PMID: 25141953 

Castelán-Martínez OD, Jiménez-Méndez R, Rodríguez-Islas F, Fierro-Evans M, Vázquez-Gómez BE, Medina-Sansón A, Clark P, Carleton B, Ross C, Hildebrand C, Castañeda-Hernández G, Rivas-Ruiz R. Hearing loss in Mexican children treated with cisplatin. Int J Pediatr Otorhinolaryngol. 2014 Sep;78(9):1456-60. PMID: 25037447

Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR. Response to “Evaluation of pharmacogenetic markers to predict the risk of cisplatin-induced ototoxicity.” Clin Pharmacol Ther. 2014 Aug;96(2):158. PMID: 24755913 

Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR. Letter to the editor “Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.” Clin Pharmacol Ther. 2014 Mar;95(3):253. PMID: 24193170

Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Feroz-Zada Y, Dube MP, Carleton BC, Hayden MR; CPNDS Consortium. Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther. 2013 Aug;94(2):243-51. PMID: 2358830 

Dionne F, Mitton C, Rassekh R, Brooks B, Ross CJ, Hayden MR, Carleton BC. Economic impact of a genetic test for cisplatin-induced ototoxicity. Pharmacogenomics J. 2012 Jun;12(3):205-13. PMID: 21502965

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; the CPNDS Consortium. Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet. 2009 Dec;41(12):1345-9. PMID: 19898482

Drug-induced nephrotoxicity:

Zazuli Z, Otten LS, Drögemöller BI, Medeiros M, Monzon JG, Wright GEB, Kollmannsberger CK, Bedard PL, Chen Z, Gelmon KA, McGoldrick N, Kitchlu A, Vijverberg SJH, Masereeuw R, Ross CJD, Liu G, Carleton BC, Maitland-van der Zee AH. Outcome Definition Influences the Relationship Between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients. Genes. 2019 May;10(5):364. PMID: 31083486 

Zazuli Z, Vijverberg S, Slob E, Liu G, Carleton B, Veltman J, Baas P, Masereeuw R, Maitland-van Der Zee AH. Genetic Variations and Cisplatin Nephrotoxicity: A Systematic Review. Front. Pharmacol. 2018 Sep 27; 9:1111. PMID: 30319427

McMahon KR, Rassekh SR, Schultz KR, Pinsk M, Blydt-Hansen T, Mammen C, Tsuyuki RT, Devarajan P, Cuvelier GD, Mitchell LG, Baruchel S, Palijan A, Carleton BC, Ross CJ, Zappitelli M, and Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Research Group. Design and Methods of the Pan-Canadian Applying Biomarkers to Minimize Long-Term Effects of Childhood/Adolescent Cancer Treatment (ABLE) Nephrotoxicity Study: A Prospective Observational Cohort Study.  Can J Kidney Health Dis. 2017 Feb 16;4:1-13. PMID: 28270931 

Medeiros M, Castañeda-Hernández G, Ross CJ, Carleton BC. Use of pharmacogenomics in pediatric renal transplant recipients. Front Genet. 2015 Feb18;6:41. PMID: 25741362

Anthracycline-induced heart failure in the treatment of cancer:

Scott E, Hasbullah JS, Ross CJD, Carleton BC. Reducing anthracycline-induced cardiotoxicity through pharmacogenetics. Pharmacogenomics. 2018 Oct;19(15):1147-1150. PMID: 30213233 

Dionne F, Aminkeng F, Bhavsar A, Groeneweg G, Smith A, Visscher H, Ross CRJ, Carleton BC. An Initial Health Economic Evaluation of Pharmacogenomic testing in Patients treated for Childhood Cancer with Anthracyclines. Pediatric Blood Cancer. 2018 Mar;65(3). PMID: 29271558

Aminkeng F, Ross CJD, Rassekh SR, Rieder MJ, Bhavsar AP, Sanatani S, Bernstein D, Hayden MR, Amstutz U, Carleton BC. Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer. Br J Clin Pharmacol. 2017 May;83(5):1143-1145. PMID: 28317142 

Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon K, Bernstein D, Hayden MR, Amstutz U, Carleton BC, CPNDS Clinical Practice Recommendations Group. Recommendations for Genetic Testing to Reduce the Incidence of Anthacycline-induced Cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. PMID: 27197003  

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nat Genet. 2015 Sep;47(9):1079-84.PMID: 26237429 

Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ; CPNDS consortium. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 2015 Jul;16(10):1065-76. PMID: 26230641

Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; the CPNDS Consortium. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer.  2013 Aug;60(8):1375-81. PMID: 23441093

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol. 2012 May;30(1):1422-8. PMID: 2190010 

Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC. Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics. J Cardiovasc Pharmacol. 2011 Sep;58(3):228-39. PMID: 21386709 

Ross CJ, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol. 2011 Mar;18:e134-51. PMID: 21467604

Vincristine-induced neuropathy in the treatment of cancer:

Nama N, Barker MK, Kwan C, Sabarre C, Solimano V, Rankin A, Raabe J, Ross CJ, Carleton B, Zwicker JG, Rassekh SR. Vincristine-induced peripheral neurotoxicity: A prospective cohort. Pediatr Hematol Oncol. 2020 Feb;37(1):15-28. PMID: 31682156

Wright GEB, Amstutz U, Drögemöller BI, Shih J, Rassekh SR, Hayden MR, Carleton BC, Ross CJD, the Canadian Pharmacogenomics Network for Drug Safety Consortium. Pharmacogenomics of vincristine-induced peripheral neuropathy implicates pharmacokinetic and inherited neuropathy genes. Clin Pharmacol Ther. 2019 Feb;105(2):402-410. PMID: 29999516

Opioid-induced toxicity:

Chau CMY, Ross CJD, Chau V, Synnes AR, Miller SP, Carleton BC, Grunau RE. Morphine Biotransformation Genes and Neonatal Clinical Factors Predicted Behaviour Problems in Very Preterm Children at 18 Months. EBioMedicine. 2019 Feb;40:655-662. PMID: 30709768

Velez de Mendizabal N, Jimenez-Mendez R, Cooke E, Montgomery C, Dawes J, Jacobo-Cabral CO, Gonzalez-Ramirez R, Castaneda-Hernandez G, Carleton BC. A compartmental analysis for morphine and its metabolites in young children after a single oral dose. Clin Pharmacokinet. 2015 Oct;54(10):1083-90. PMID: 25773480

Baber M, Chaudhry S, Kelly L, Ross C, Carleton BC, Koren G. The pharmacogenetics of codeine pain relief in the postpartum period. Pharmacogenomics J. 2015 Oct;15(5):430-5. PMID: 25752520.

Smolina K, Weymann D, Morgan S. Ross C, Carleton B.  Association between regulatory advisories and codeine prescribing to postpartum women. Jama. 2015 May: 313(18):1861-2. PMID: 25965237 

Lam J, Woodall KL, Solbeck P, Ross CJ, Carleton BC, Hayden MR, Koren G, Madadi P. Codeine-related deaths: The role of pharmacogenetics and drug interactions. Forensic Sci Int 2014 Jun;239:50-6. PMID: 24747667 

Lam J, Kelly L, Matok I, Ross CJ, Carleton BC, Hayden MR, Madadi P, Koren G. Putative association of ABCB1 2677G>T/A with oxycodone-induced central nervous system depression in breastfeeding mothers. Ther Drug Monit. 2013 Aug;35(4):466-472. PMID: 23783165 

Kelly LE, Chaudhry SA, Rieder MJ, ‘t Jong G, Moretti ME, Lausman A, Ross C, Berger H, Carleton B, Hayden MR, Madadi P, Gideon K. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. PLOS ONE. 2013 Jul;8(7):e70073. PMID: 23922910

Madadi P, Sistonen J, Silverman G, Gladdy R, Ross CJ, Carleton BC, Carvalho JC, Hayden MR, Koren G. Life-threatening adverse events following therapeutic opioid administration in adults: Is pharmacogenetic analysis useful?Pain Res Manag. 2013 May-June;18(3):133-6. PMID: 23748253 

Khetani JD, Madadi P, Sommer DD, Reddy D, Sistonen J, Ross CJ, Carleton BC, Hayden MR, Koren G. Apnea and oxygen desaturations in children treated with opioids after adenotonsillectomy for obstructive sleep apnea syndrome. Pediatr Drugs. 2012 Dec;14(6):411-415. PMID: 23013460

Lam J, Matlow JN, Ross CJ, Hayden MR, Carleton BC, Madadi P. Postpartum maternal codeine therapy and the risk of adverse neonatal outcomes: The devil is in the details. Ther Drug Monit. 2012 Aug;34(4):378-80. PMID: 22777151

Kelly LE, Rieder M, van den Anker J, Malkin B, Ross CJ, Neely MN, Carleton BC, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 2012 May;129(5):e1343-7. PMID: 22492761 

Shaw K, Amstutz U, Jimenez-Mendez R, Ross CJ, Carleton BC. Suspected opioid overdose case resolved by CYP2D6 genotyping. Ther Drug Monit. 2012 Apr;34(2):121-3. PMID: 22406651 

Sistonen J, Madadi P, Ross CJ, Yazdanpanah M, Lee JW, Landsmeer MLA, Nauta M, Carleton BC, Koren G, Hayden MR. Prediction of codeine toxicity in infants and their mothers using a novel combination of maternal genetic markers. Clin Pharmacol Ther. 2012 Apr;91(4):692-9. PMID: 22398969 

Lam J, Kelly L, Ciszkowski C, Landsmeer ML, Nauta M, Carleton BC, Hayden MR, Madadi P, Koren G. Central nervous system depression of neonates breastfed by mothers receiving oxycodone for postpartum analgesia. J Pediatr. 2012 Jan;160(1):33-7. PMID: 21880331

VanderVaart S, Berger H, Sistonen J, Madadi P, Matok I, Gijsen VM, de Wildt SN, Taddio A, Ross CJ, Carleton BC, Hayden MR, Koren G. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study. Ther Drug Monit. 2011 Aug;33(4):425-32. PMID: 21743374 

Madadi P, Hildebrant D, Gong IY, Schwarz UI, Ciszkowski C, Ross CJD, Sistonen J, Carleton BC, Hayden MR, Lauwers AE, Koren G. Fatal hydrocodone overdose in child: pharmacogenetics and drug interactions. Pediatrics. 2010 Oct;126(4):e986-9 PMID: 20837591 

Madadi P, Ross CJD, Hayden MR, Carleton BC, Gaedigk A, Leeder SJ, Koren G. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009 Jan;85(1):31-5. PMID: 18719619

Warfarin-induced bleeding:

Takeuchi M, Kobayashi T, Biss T, Kamali F, Vear SI, Ho RH, Bajolle F, Loriot MA, Shaw K, Carleton BC, Hamberg AK, Wadelius M, Hirono K, Taguchi M, Wakamiya T, Yanagimachi M, Hirai K, Itoh K, Brandão LR, Ito S. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis. Pharmacogenomics J. 2020 Apr;20(2):306-319. PMID: 31673144

Aminkeng F. Using pharmacogenetics in real time to guide therapy: the warfarin example. Clin Genet. 2014 Jun;85(6):533-4. PMID: 24628520

Shaw K, Amstutz U, Hildebrand C, Rassekh SR, Hosking M, Neville K, Leeder SJ, Hayden M, Ross CJ, Carleton BC. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children. Ped Blood Cancer. 2014 Jun;61(6):1055-62. PMID: 24474498

Carleton BC. Gene-based warfarin dosing. Ther Drug Monit. 2010 Jun;32(3):332 PMID: 20498559

 

Drug-induced serious skin reactions: 

Chang W, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, Bellón T, Biala AK, Bouchard C, Cavalleri GL, Chapman N, Chodosh J, Choi HK, Cibotti RR, Divito SJ, Dewar K, Dehaeck U, Etminan M, Forbes D, Fuchs E, Goldman JL, Holmes JH, Hope EA, Hung S, Hsieh C, Iovieno A, Jagdeo J, Kim MK, Koelle DM, Lacouture ME, Le Pallec S, Lehloenya RJ, Lim R, Lowe A, McCawley J, McCawley J, Micheletti RG, Mockenhaupt M, Niemeyer K, Norcross MA, Oboh D, Olteanu C, Pasieka HB, Peter J, Pirmohamed M, Rieder M, Saeed HN, Shear NH, Shieh C, Straus S, Sukasem C, Sung C, Trubiano JA, Tsou S, Ueta M, Volpi S, Wan C, Wang H, Wang Z, Weintraub J, Whale C, Wheatley LM, Whyte-Croasdaile S, Williams KB, Wright G, Yeung SN, Zhou L, Chung W, Phillips EJ, Carleton BC. SJS/TEN 2019: From Science to Translation. J Dermatol Sci. 2020 Mar 7:S0923-1811(20)30064-5. PMID: 32192826

White KD, Abe R, Ardern-Jones M, Beachkofsky T, Bouchard C, Carleton B, Chodosh J, Cibotti R, Davis R, Denny JC, Dodiuk-Gad RP, Ergen EN, Goldman JL, Holmes JH 4th, Hung SI, Lacouture ME, Lehloenya RJ, Mallal S, Manolio TA, Micheletti RG, Mitchell CM, Mockenhaupt M, Ostrov DA, Pavlos R, Pirmohamed M, Pope E, Redwood A, Rosenbach M, Rosenblum MD, Roujeau JC, Saavedra AP, Saeed HN, Struewing JP, Sueki H, Sukasem C, Sung C, Trubiano JA, Weintraub J, Wheatley LM, Williams KB, Worley B, Chung WH, Shear NH, Phillips EJ. SJS /TEN 2017: Building Multidisiplinary Networks to Drive Science and Translation.  J Allergy Clin Immunol Pract. 2018 Jan – Feb;6(1):38-69. PMID: 29310768 

McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, Becker F, Rau S, Avbersek A, Heggeli K, Leu C, Depondt C, Sills GJ, Marson AG, Auce P, Brodie MJ, Francis B, Johnson MR, Koeleman BPC, Striano P, Coppola A, Zara F, Kunz WS, Sander JW, Lerche H, Klein KM, Weckhuysen S, Krenn M, Gudmundsson LJ, Stefánsson K, Krause R, Shear N, Ross CJD, Delanty N; EPIGEN Consortium; Pirmohamed M, Carleton BC; Canadian Pharmacogenomics Network for Drug Safety; Cendes F, Lopes-Cendes I, Liao WP, O’Brien TJ, Sisodiya SM; EpiPGX Consortium; Cherny S, Kwan P, Baum L; International League Against Epilepsy Consortium on Complex Epilepsies; Cavalleri GL. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients. Neurology. 2018 Jan 23;90(4):e332-e341. PMID: 29288229  

McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang EJ, Secolin R, Yasuda C, Kwok M, Wolking S, Becker F, Rau S, Avbersek A, Heggeli K, Leu C, Depondt C, Sills GJ, Marson AG, Auce P, Brodie MJ, Francis B, Johnson MR, Koeleman BPC, Striano P, Coppola A, Zara F, Kunz WS, Sander JW, Lerche H, Klein KM, Weckhuysen S, Krenn M, Gudmundsson LJ, Stefánsson K, Krause R, Shear N, Ross CJD, Delanty N; EPIGEN Consortium; Pirmohamed M, Carleton BC; Canadian Pharmacogenomics Network for Drug Safety; Cendes F, Lopes-Cendes I, Liao WP, O’Brien TJ, Sisodiya SM; EpiPGX Consortium; Cherny S, Kwan P, Baum L; International League Against Epilepsy Consortium on Complex Epilepsies; Cavalleri GL. Genetic variation in CFH predicts phenytoin-induced maculopapular exanthema in European-descent patients.Neurology. 2018 Jan 23;90(4):e332-e341. PMID: 29288229 

Amstutz U, Ross CJD, Castro-Pastrana LI, Rieder MJ, Shear NH, Hayden MR, Carleton BC. HLA-A*31:01 and HLA-B*15:02 as genetic markers for carbamazepine hypersensitivity in children. Clin Pharmacol Ther. 2013 Jul;94(1):142-9. PMID: 23588310 

Pirmohamed M, Friedmann PS, Molokhia M, Loke YK, Smith C, Phillips E, La Grenade L, Carleton BC, Papaluca-Amati M, Demoly P, Shear NH. Phenotype standardization for immune-mediated drug-induced skin injury.Clin Pharmacol Ther. 2011 Jun;89(6):896-901. PMID: 21562486 

Castro-Pastrana LI, Ghannadan R, Rieder MJ, Dahlke E, Hayden M, Carleton BC. Cutaneous adverse drug reactions in children: an analysis of reports from the Canadian Pharmacogenomics Network for Drug Safety (CPNDS). J Popul Ther Clin Pharmacol. 2011 Mar;18:e106-20. PMID: 21467602 

Del Pozzo-Magana BR, Lazo-Langner A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of treatment of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Pharmacol. 2011 Mar;18:e121-33. PMID: 21467603 

Ito S, Carleton BC. Predictive genotype for carbamazepine-induced severe skin reactions. CMAJ. 2010 May 18;182(8):804. (Letter) PMID: 20479057

 

Beta-interferon induced liver injury in the treatment of MS patients: 

Wright G, Drögemöller B, Ross CJD, Carleton B. Genome-wide association studies of drug induced liver injury make progress beyond the HLA region (Letter to the Editor). Gastroenterology. 2019 Oct;157(4):1167-1168. PMID: 31348928

Kowalec K, Wright GEB, Drögemöller BI, Aminkeng F, Bhavsar AP, Kingwell E, Yoshida EM, Traboulsee A, Marrie RA, Kremenchutzky M, Campbell TL, Duquette P, Chalasani N, Wadelius M, Hallberg P, Xia Z, De Jager PL, Denny JC, Davis MF, Ross CJD, Tremlett H, Carleton BC. Common variation near IRF6 is associated with IFN-β-induced liver injury in multiple sclerosis. Nat Genet. 2018 Aug;50(8):1081-1085. PMID: 30013178 

Kowalec K, Kingwell E, Carruthers R, Marrie RA, Bernatsky S, Traboulsee A, Ross CJD, Carleton BC, Tremlett H. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. BMJ Open. 2017 Jun 2;7(5):e016276. PMID: 28576902 

Kowalec K, Kingwell E, Yoshida EM, Marrie RA, Kremenchutzky M, Campbell TL, Wadelius M, Carleton B, Tremlett H. Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf. 2014 Oct;13(10):1305-17. PMID: 25134421

Kowalec K, Carleton BC and Tremlett H. The potential role of pharmacogenomics in the prevention of serious adverse drug reactions in multiple sclerosis. Multiple Sclerosis and Related Disorders. 2013 Jul;2(3):183-192. PMID: 25877724 

Kowalec K, Yoshida EM, Traboulsee A, Carleton BC and Tremlett H. Suspected autoimmune hepatitis and primary biliary cirrhosis unmasked by interferon-beta in a multiple sclerosis patient. Mult Scler Relat Disord. 2013 Jan;2(1):57-59. PMID: 25877455

 

Pharmacogenomic Diversity and Drug Safety in World-wide Populations:

King C, McKenna A, Farzan N, Vijverberg S, van der Schee M, Maitland-van der Zee A, Arianto L, Bisgaard H, BØnnelykke K, Berce V, PotoČnik U, Repnik K, Carleton B, Daley D, Chew FT, Chiang W, Sio YY, Cloutier M, Den Dekker H, Duijts L, de Jongste JC, Dijk FN, Flores C, Hernandez-Pacheco N, Mukhopadhyay S, Basu K, Bignell L, Tantisira K, Verhamme K, Celedon J, Forno E, Canino G, Francis B, Pirmohamed M, Sinha I, Hawcutt D.  Pharmacogenomic associations of adverse drug reactions in asthma: systematic review and research prioritization. Pharmacogenomics J. 2020 Jan 17. PMID: 31949291

Tanoshima R, Khan A, Biala AK, Trueman JN, Drögemöller BI, Wright GEB, Hasbullah JS, Groeneweg GSS, Ross CJD, Carleton BC. Analyses of Adverse Drug Reactions Nationwide Active Surveillance Network: Canadian Pharmacogenomics Network for Drug Safety (CPNDS) database. J Clin Pharmacol. 2019 Mar;59(3):356-363. PMID: 30452777 

Clemens E, van der Kooi ALF, Broer L, van Dulmen-den Broeder E, Visscher H, Kremer L, Tissing W, Loonen J, Ronckers CM, Pluijm SMF, Neggers SJCMM, Zolk O, Langer T, am Zehnhoff-Dinnesen, Wilson CL, Hudson MM, Carleton B, Laven JSE, Uitterlinden AG, van den Heuvel-Eibrink MM. The Influence of Genetic Variation on Late Toxicities in Childhood Cancer Survivors: A Review. Crit Rev Oncol Hematol. 2018 June;126:154-167. PMID: 29759558 

McLaughlin MJ, He Y, Brunstrom-Hernandez J, Thio LL, Carleton BC, Ross CJD, Gaedigk A, Lewandowski A, Dai H, Jusko WJ, Leeder JS. Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children with Cerebral Palsy. PM R. 2018 Mar;10(3):235-243. PMID: 28867665 

Wright G, Carleton B, Hayden M, Ross C. The global spectrum of protein-coding pharmacogenomics diversity.  Pharmacogenomics J. 2018 Jan;18(1):187-195. PMID: 27779249 

Etminan M, Sodhi M, Procyshyn R, Guo M, Carleton B. Risk of Hair Loss with Different Antidepressants: A Comparative Retrospective Cohort Study. Intl Clin Psychopharmacol. 2018 Jan;33(1):44-48. PMID: 28763345

Farzan N, Vijverberg SJ, Andiappan AK, Arianto L, Berce V, Blanca-López N, Bisgaard H, Bønnelykke K, Burchard EG, Campo P, Canino G, Carleton B, Celedón JC, Chew FT, Chiang WC, Cloutier MM, Daley D, Den Dekker HT, Dijk FN, Duijts , Flores C, Forno E, Hawcutt DB, Hernandez-Pacheco N, de Jongste JC, Kabesch M, Koppelman GH, Manolopoulos VG, Melén E, Mukhopadhyay S, Nilsson S, Palmer CN, Pino-Yanes M, Pirmohamed M, Potočnik U, Raaijmakers J, Repnik K, Schieck M, Sio YY, Smyth RL, Szalai C, Tantisira KG, Turner S, van der Schee MP, Verhamme KM, Maitland-van der Zee AH. Rationale and design of the multiethnic Pharmacogenomics in Childhood Asthma consortium. Pharmacogenomics. 2017 Jul;18(10):931-943. PMID: 28639505

Etminan M, Sodhi M, Samii A, Procyshyn RM, Guo M, Carleton BC. Risk of Gambling Disorders and Impulse Control Disorder with Aripiprazole Pramipexole and Ropinirole: A Pharmacoepidemiologic Study. J Clin Psychopharmacol. 2017 Feb;37(1):102-104. PMID: 27930495

Torosyan Y, Hu Y, Hoffman S, Lou Q, Carleton B, Marinac-Dabic D. An In Silico Framework for Integrating Epidemiologic and Genetic Evidence with Health Care Applications: Ventilation-Related Pneumothorax as a Case Illustration. J Am Inform Med Assoc. 2016 Jul;23(4):711-20. PMID: 27107435 

Jimenez R, Smith A, Carleton B. New ways of detecting ADRs in neonates and children. Curr Pharm Des. 2015;21(39):5643-9. PMID: 26323415 

Buxton JA, Omura J, Kuo M, Ross C, Tzemis D, Purssell R, Gardy J, Carleton B. Genetic determinants of cocaine-associated agranulocytosis. BMC Res Notes 2015 Jun;13;8:240. PMID: 26070312 

Aminkeng F, Ross CJ, Rassekh SR, Brunham LR, Sistonen J, Dube MP, Ibrahim M, Nyambo TB, Omar SA, Froment A, Bodo JM, Tishkoff S, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium. Higher frequency of genetic variants conferring increased risk for ADRs for commonly used drugs treating cancer, AIDS and tuberculosis in persons of African descent. Pharmacogenomics J. 2014 Apr;14(2):160-170. PMID: 23588107

Brunham LR, Chan SL, Li R, Aminkeng F, Liu X, Saw WY, Ong RT, Pillai EN, Carleton BC, Toh D, Tan SH, Koo SH, Lee EJ, Chia KS, Ross CJ, Hayden MR, Sung C, Teo YY. Pharmacogenomic diversity in Singaporean populations and Europeans. Pharmacogenomics J. 2014 Dec;14(6):555-563. PMID: 24861855 

Chan SL, Samaranayake N, Ross CJ, Toh MT, Carleton BC, Hayden MR, Teo YY, Dissanayake VH, Brunham LR.  Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: Implications for clinical implementation of pharmacogenomics.  Pharmacogenet Genomics. 2016 Jan;26(1):28-39. PMID: 26444257

 

Machine Learning and Big Data in Drug Safety: 

McMahon AW, Cooper WO, Brown JS, Carleton B, Doshi-Velez F, Kohane I, Goldman JL, Hoffman MA, Kamaleswaran R, Sakiyama M, Sekine S, Sturkenboom MC, Turner MA, Califf RM. Big Data in the Assessment of Pediatric Medication Safety. Pediatrics. 2020 Feb;145(2):e20190562. PMID: 31937606

Mansouri M, Yuan B, Ross CJD, Carleton BC, Ester M. HUME: Large-scale Detection of Causal Genetic Factors of Adverse Drug Reactions. Bioinformatics. 2018 Dec 15;34(24):4274-4283. PMID: 29931042

 

Clinical Practice Guidelines / Recommendations:

Loucks C, Groeneweg G, Roy C, Lee DK, Rieder MJ, Lebel D, Ito S, Ross CJ, Carleton BC. Pharmacogenomic testing: the key to enhancing personalized medication use for patients. Can Fam Physician. 2020 Apr;66(4):241-243. PMID: 32273406 

McLaughlin M, Wagner J, Shakhnovich V, Carleton B, Leeder J. Considerations for Implementing Precision Therapeutics for Children. Clin Transl Sci. 2019 Mar;12(2):140-150. PMID: 30516322

Drögemöller BI, Wright GEB, Shih J, Monzon J, Gelmon KA, Ross CJD, Amstutz U, Carleton BC on behalf of the CPNDS Clinical Recommendations Group. CYP2D6 as a treatment decision aid for ER-positive non-metastatic breast cancer patients: a systematic review with accompanying clinical practice guidelines. Breast Cancer Res Treat. 2019 Feb;173(3):521-532. PMID: 3041124 

Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, Bonne NX, Brock PR, Brooks B, Carleton B, Caron E, Chang KW, Johnston K, Knight K, Nathan PC, Orgel E, Prasad PK, Rottenberg J, Scheinemann K, de Vries ACH, Walwyn T, Weiss A, Am Zehnhoff-Dinnesen A, Cohn RJ, Landier W; International Guideline Harmonization Group ototoxicity group. Recommendations for Ototoxicity Surveillance for Childhood, Adolescent, and Young Adult Cancer Survivors: A Report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium.Lancet Oncol. 2019 Jan;20(1):e29-e41. PMID: 3061447 

Phillips E, Sukasem C, Whirl-Carrillo M, Müller D, Dunnenberger H, Chantratita W, Goldspiel B, Chen YT, Carleton BC, George A, Mushiroda T, Klein T, Gammal R, Pirmohamed M. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018 Apr;103(4):574-581. PMID: 29392710

Aminkeng F, Ross CJ, Rassekh SR, Hwang S, Rieder MJ, Bhavsar AP, Smith A, Sanatani S, Gelmon KA, Bernstein D, Hayden MR, Amstutz U, Carleton BC and the CPNDS clinical recommendations group.  Recommendations for Genetic Testing to Reduce the Incidence of Anthracycline-induced Cardiotoxicity. Br J Clin Pharmacol. 2016 Sep;82(3):683-95. PMID: 27197003

Lee JW, Pussegoda K, Rassekh SR, Monzon JG, Liu G, Hwang S, Bhavsar AP, Pritchard S, Ross CJ, Amstutz U, Carleton BC and the CPNDS clinical recommendations group.  Clinical Practice Recommendations for the Management and Prevention of Cisplatin-induced Hearing Loss using Pharmacogenomics Markers. Ther Drug Monit. 2016 Aug;38(4):423-31. PMID: 2696017 

Maagdenberg H, Vijverberg SJ, Bierings MB, Carleton BC, Arets HG, de Boer A, Maitland-van der Zee AH. Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. Paediatr Drugs. 2016 Aug;18(4):251-60. PMID: 2714247 

Syme R, Carleton B, Leyens L, Richer E. Integrating Personalized Medicine in the Canadian Environment: Efforts Facilitating Oncology Clinical Research. Public Health Genomics. 2015 Nov:18(6):372-80 PMID: 26565702

Shaw K, Amstutz U, Kim R, Lesko LJ, Rhoades J, Turgeon J, Michaud V, Hwang S, Ito S, Carleton BC and the CPNDS clinical recommendations group. Clinical Practice Recommendations on Genetic Testing of CYP2C9 and VKORC1 variants in Warfarin Therapy. Ther Drug Monit. 2015 Aug;37(4):428-36. PMID: 26186657

Amstutz U, Shear NH, Rieder MJ, Hwang S, Fung V, Nakamura H, Connolly MB, Ito S, Carleton BC, the CPNDS clinical recommendation group. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia. 2014 Apr;55(4):496-506. PMID: 24597466

Madadi P, Amstutz U, Rieder M, Ito S, Fung V, Hwang S, Turgeon J, Michaud V, Koren G, Carleton BC, CPNDS Clinical Recommendations Group. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy. J Popul Ther Clin Pharmacol. 2013 Nov; 20(3): e369-e396. PMID: 24214521

Amstutz U, Carleton BC. Pharmacogenetic testing: time for clinical practice guidelines. Clin Pharmacol Ther. 2011 Jun;89(6):924-7. PMID: 21508939